Apexigen EBIT

Apexigen (APGN) currently reports a EBIT of $-28M as of June 2023. That compares with $-1.8B in the prior-year period — up 98.5% year over year. That is above the sector sector average of $-63M. Use the charts on this page to explore Apexigen's EBIT history and peer comparisons.

Apexigen's EBIT increased from $-1.8B to $-28M — a 98.5% year-over-year increase (period ending June 2023). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Apexigen's EBIT of $-28M is higher than the its sector sector average of $-63M. That is roughly 55.5% above the sector mean. A reading higher peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

Apexigen reported $-28M in EBIT as of June 2023. That compares with $-1.8B in the prior-year period — up 98.5% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current EBIT of $-28M, then check the historical chart for trend and the peer comparison chart for relative positioning. The sector average is $-63M. From there, open related valuation or income-statement pages for Apexigen, and consider following APGN for alerts when major investors trade the stock.